Humana to Cover Agendia's MammaPrint | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agendia today announced that insurer Humana will provide reimbursement for the firm's MammaPrint breast cancer recurrence test.

The Dutch molecular diagnostics firm said that the contract with Humana will expand coverage for MammaPrint by more than 17 million lives. Coding guidelines for the test were established in November 2009 by Palmetto GBA, California's Part B Medicare administrator.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.